ClinicalTrials.gg
CompletedNCT06432764Updated Apr 14, 2026

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

A Phase 1 interventional study of AZD7798 and [11C]AZ14132516 in Crohn Disease, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Crohn Disease by AstraZeneca — none open to participants now, 2 under way, none of them phase 3. Crohn Disease · AstraZeneca.

Enrollment
13th of 13
9 · median 48
Started
2024
with 2 others
Phase 1
5 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Crohn Disease by AstraZeneca, this one is the 13th largest by enrollment, is one of 3 that started in 2024, is one of 5 in phase 1, and was the 12th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 13 studies in Crohn Disease by AstraZeneca is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Crohn Disease by AstraZeneca as a file.
02

Study summary

The purpose of this study is to measure the changes in intestinal uptake of radioligand [11C]AZ14132516 following multiple doses of AZD7798 in participants with Crohn's disease.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 20 to 80 years of age, inclusive, at the time of signing the .
  • Participants with confirmed Crohn's disease with small bowel involvement (Montreal terminal ileum [L1] or ileocolon [L3]) per study gastroenterologist (diagnosed via combination of clinical findings and at least one of endoscopy and/or histology and/or imaging) with diagnosis made at least 6 months before screening.
  • Participants with active Crohn's disease as determined by one of the following:

    1. Evidence of active inflammation on cross-sectional imaging (CT, MRI or bowel ultrasound scan) or endoscopy within 6 months before screening OR EITHER
    2. If no cross-sectional imaging or endoscopy performed within 6 months before screening, a bowel ultrasound scan may be performed to confirm active disease OR
    3. If no cross-sectional imaging or endoscopy performed within 6 months before screening, elevated faecal calprotectin AND CRP
  • Body habitus compatible with PET examination.
  • use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent
  • Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.

Exclusion criteria

Exclusion Criteria:

  • Other form of IBD or concomitant, additional, active GI luminal inflammatory diseases.
  • CMV colitis within 12 months before screening.
  • Crohn's complications including short bowel syndrome, strictures that are symptomatic or with pre-stenotic dilatation or other conditions where surgery anticipated during study period.
  • Planned bowel or perianal surgery within 6 months before screening.
  • Bowel resection surgery within 6 months before screening.
  • Undrained fistula or abscess (including active perianal disease).
  • Positive Clostridium difficile toxin test during screening.
  • Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease, renal disease, GI disease, or other major diseases other than active Crohn's disease and associated extra-intestinal manifestations.
  • Ongoing psychiatric conditions that in the opinion of the Investigator, precludes study participation.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to biologic therapies.
  • Participants with unstable hypertension (as judged by the Investigator) or symptomatic hypotension, history of pre-syncope or syncope due to orthostatic hypotension and/or induced by change of posture.
  • Significant abnormalities on clinical examination, including neurological and physical examination, vital signs, and , other than signs of Crohn's disease.
  • Clinical chemistry, haematology, or urine analysis results that may interfere with the study or present a safety risk to the participant.
  • Abnormal vital signs, after 10 minutes of supine rest as judged by the Investigator.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG that may interfere with the interpretation of changes.
  • Positive , , or serology
  • Treatment with an anti-TNF within 8 weeks of the first dose and throughout the study period, before the first dose and throughout study period, unless therapeutic drug monitoring is performed, and drug concentrations are undetectable.
  • Treatment with any biologic, other than an anti-TNF (including vedolizumab and ustekinumab) within 12 weeks prior to first dose and throughout the study period, unless therapeutic drug monitoring is performed, and drug concentrations are undetectable.
  • Treatment with rituximab within 12 months before first dose and throughout the study period.
  • Treatment with Sphigosine-1-phosphate receptor modulators or Janus kinase inhibitors within 4 weeks before first dose and throughout the study period.
  • Treatment with apheresis (eg, Adacolumn, Cellsorba) within 2 weeks prior to first dose and throughout the study period.
  • Treatment with at a total daily dose of greater than 20 mg prednisone or equivalent (greater than 9 mg budesonide).
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or site staff).
  • Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  • Suffers from claustrophobia that limits the ability to undergo the scanning procedure.
  • Positive SARS-CoV-2 rapid antigen test at screening.
  • Any other reason that, in the study Investigator opinion, prohibits the inclusion of the participants into the study.
  • Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  • Live or attenuated vaccine within 4 weeks before screening and until 12 weeks after the end of the follow-up period (1 year for Bacillus Calmette-Guérin vaccination).
  • An active infection, or history of serious infection within 28 days before screening.
  • History of symptomatic herpes simplex (excluding cold sores) or herpes zoster infection within 3 months prior to screening.
  • Positive or indeterminate TB QuantiFERON test performed within 1 year of screening (without known interval exposure to TB) or during screening period unless evidence of completion of full treatment course for latent TB with no clinical symptoms or signs indicative of re activation.
  • Chest x-ray with signs of or latent or active TB infection performed within 1 year of screening (without known interval exposure to TB) or during screening period.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days/5 half-lives, whichever is longer, of the first administration of IMP in this study. The period of exclusion begins 30 days/5 half-lives after the final dose, whichever is longer, .
  • Current malignancy or history of malignancy, except for:

    1. Basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to screening.
    2. Other non-GI malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years before screening.
  • For females only: Currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    AZD7798

    Arm consists of up to 2 panels

    Drug: AZD7798 · Drug: [11C]AZ14132516

Interventions

  • Each participating patient will receive the study drug as specified in the study protocol.

    Also known as: Study Drug

  • Drug[11C]AZ14132516

    A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination

    Also known as: Radioligand

06

What researchers measure

Primary outcomes

  1. Change from baseline in intestinal SUV/SUVR

    Standardized uptake value (SUV) is the radioactivity concentration in given region of interest normalized for injected radioactivity and body weight. Standardised uptake value ratio (SUVR) is the ratio of SUV in a given region of interest to a reference region without significant radioligand uptake

    Time frame: Weeks 13, 16, 20 and 24 (may vary between participants)

Secondary outcomes

  1. Serum AZD7798 concentration

    Time frame: Weeks 0, 4, 8, 12 (may vary between participants)

  2. Incidence and titre of anti-drug antibodies

    Time frame: Week 0, 4, 8, 12 and 24 (may vary between participants)

Other outcomes

  1. Number of participants with safety findings, AEs

    Safety will be assessed by Adverse Events, vital signs, haematology and clinical chemistry

    Time frame: Until final follow-up, week 24 (may vary between participants)

07

Study locations

1 site
  • Research Site
    Stockholm, 14186, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2026, 17 months.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 17 months is close to that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 29, 2024
StartActual
Oct 16, 2024
Primary completionActual
Mar 27, 2026
CompletionActual
Mar 27, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06432764
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Oct 16, 2024
Primary completion
Mar 27, 2026
Completion
Mar 27, 2026
Last update
Apr 14, 2026

Study contacts

Maria Creignou
principal investigator · Karolinska University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD7798

Start the discussion